BUZZ-肥胖症药物数据不尽如人意,安进公司市值将缩水 160 亿美元

Reuters
26 Nov 2024

((自动化翻译由路透提供,请见免责声明 )) (更新)

11月26日 - ** 安进公司 股价下跌19%至265.06美元

** 股价创下七个多月新低,如果跌势持续,市值将减少 160 亿美元。

** 该公司的实验性药物MariTide导致平均体重下降达20% (link),一些分析师称这是投资者的最低标准。

** 杰富瑞(Jefferies)分析师迈克尔-易(Michael Yee)说,该药物的疗效与其他获批药物一致,但 "低于20%-25%的预期"。

** 11月12日,AMGN的股价下跌了7%,因为Cantor Fitzgerald的分析师称,他们对该药物早期数据的审查显示,骨矿密度 (link),这可能会增加骨折的风险。

** AMGN股价今年以来已下跌 约8% ,其中包括盘中走势

<^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ Amgen stock performance

^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^>

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10